BriaCell Therapeutics Corp (NASDAQ:BCTX) has a beta value of 1.12 and has seen 23.22 million shares traded in the last trading session. The company, currently valued at $5.23M, closed the last trade at $0.77 per share which meant it lost -$1.25 on the day or -61.78% during that session. The BCTX stock price is -3718.18% off its 52-week high price of $29.40 and -155.84% below the 52-week low of $1.97. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.51 million shares traded. The 3-month trading volume is 1.79 million shares.
BriaCell Therapeutics Corp (NASDAQ:BCTX) trade information
Sporting -61.78% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the BCTX stock price touched $0.77 or saw a rise of 67.37%. Year-to-date, BriaCell Therapeutics Corp shares have moved -94.36%, while the 5-day performance has seen it change -73.47%. Over the past 30 days, the shares of BriaCell Therapeutics Corp (NASDAQ:BCTX) have changed -78.13%. Short interest in the company has seen 0.21 million shares shorted with days to cover at 0.31.
BriaCell Therapeutics Corp (BCTX) estimates and forecasts
The company’s shares have lost -87.22% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 47.85% over the past 5 years. Earnings growth for 2025 is a modest 41.56% while over the next 5 years, the company’s earnings are expected to increase by 31.60%.
BCTX Dividends
BriaCell Therapeutics Corp is expected to release its next earnings report on 2025-Jun-16 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
BriaCell Therapeutics Corp (NASDAQ:BCTX)’s Major holders
Insiders own 7.33% of the company shares, while shares held by institutions stand at 10.88% with a share float percentage of 11.74%. Investors are also buoyed by the number of investors in a company, with BriaCell Therapeutics Corp having a total of 18.0 institutions that hold shares in the company.
